| Metric | Grade | Score | Evidence | Horizon |
|---|---|---|---|---|
| FINAL ESEN MASTER SCORE | B+ | 73 | Balanced defensive profile with modest growth, reasonable valuation, solid dividend support | 6–12M |
| SA Quality/Value Composite | B | 68 | P/E 15.86x reasonable for staples; forward P/E 16.20x; dividend yield 4.73% attractive; revenue decline offset by EPS growth 10.56% | 6–12M |
| Zacks Earnings Momentum | A− | 78 | EPS growth YoY +10.56% strong; PEG 1.50x reasonable; EPS 6.16 per share solid fundamentals | 3–6M |
| Institutional & Smart Money Flow | B | 65 | Price +0.28% today; 52W return −15.86% reflects macro pressure; avg volume 2.88M modest; no earnings surprise catalyst near-term | 1–3M |
| Growth Sustainability & Moat | B | 70 | Consumer staples secular franchise; revenue YoY −3.69% headwind; beta 0.576 defensive; eps growth offsetting; iconic brand moat | 12M+ |
| Valuation & Safety (Pre-Penalty) | A− | 80 | P/E 15.86x below historical average; dividend safety solid with 4.88 DPS; market cap 12.8B stable; 52W high 128.9, low 84.7 range | 6–12M |
| Penalty Overlay | −5 | −5 | Revenue decline −3.69% YoY structural pressure; 52W underperformance −15.86%; no high-growth or hyper-growth flags; modest macro sensitivity | 6–12M |
| CONFIDENCE SCORE | A | 85 | High-quality institutional data; strong fundamental transparency; beta 0.576 predictable; dividend history reliable; earnings visibility limited near-term | 6–12M |
| Volatility & Drawdown Risk | A | 82 | Beta 0.576 well below market; 52W drawdown from 128.9→104.77 (−18.8%) moderate; defensive name; low systematic risk | 6–12M |
| Crowding Risk Flag | B | 72 | Dividend yield 4.73% attracts income investors; consumer staples sector crowded; CLX mid-cap stable flow; no extreme positioning evident | 1–3M |
Clorox operates in the consumer staples sector, competing with peers like Procter & Gamble (PG), Colgate-Palmolive (CL), and Church & Dwight (CHD). CLX's P/E of 15.86x sits below PG (~27x) and near CL (~21x), reflecting its more modest growth profile but attractive value positioning. The 4.73% dividend yield significantly outpaces sector average (~2.5%), making it appealing to income-focused institutional allocators. However, the −3.69% revenue YoY decline and 52-week underperformance (−15.86%) signal structural headwinds in consumer volumes and promotional intensity. EPS growth of +10.56% (partly from buybacks and margin management) provides a degree of earnings resilience, but top-line weakness remains a concern. Beta of 0.576 confirms CLX's defensive positioning, typically outperforming in risk-off environments but underperforming in growth rotations.
| Horizon | View & Drivers | Key Catalysts / Risks |
|---|---|---|
| 1–3 Months | HOLD Near-term momentum weak; price up only +0.28% today; avg volume 2.88M indicates modest institutional accumulation. EPS momentum is positive, but near-term catalyst visibility constrained. Dividend support (~$1.22 quarterly) provides floor. Macro uncertainty and continued revenue pressure likely to keep stock range-bound 104–108. |
Upside: Q3 earnings beat on margin management, dividend confidence reaffirmed. Downside: Consumer spending slowdown, competitive pricing pressure, macro recession fears. |
| 6–12 Months | BUY (TACTICAL) Valuation support at 15.86x P/E and 4.73% yield should anchor downside; EPS growth +10.56% sustainable if operational leverage maintained. Defensive moat (brand, category leadership) and low beta (0.576) ideal for conservative allocators and dividend reinvestment programs. Target range 110–118 (~4–11% upside) if earnings expectations stabilize and macro sentiment improves. |
Upside: Revenue stabilization, margin expansion, dividend raise confirmation, sector rotation into staples. Downside: Further volume declines, competitive margin compression, dividend cut risk if FCF deteriorates. |
CLX is a defensive-income staple with solid dividend support (4.73% yield), reasonable valuation (15.86x P/E, 1.50x PEG), and strong near-term EPS momentum (+10.56% YoY). The low-beta profile (0.576) and iconic brand moat provide resilience in downturns. However, structural revenue headwinds (−3.69% YoY), 52-week underperformance (−15.86%), and limited near-term growth catalysts warrant a cautious-overweight stance for income-focused and risk-averse portfolios. Recommended positioning: Core holding for dividend reinvestment; tactical accumulation on weakness below $103; monitor Q3 earnings for revenue stabilization signals. Fair value 110–115 over 6–12M horizon.
CLX Analyst Price Target Forecast - ESEN Analytics
CLX analyst price target: $117.0 average (range $94.0-$163.0), based on 27 Wall Street analysts.
ESEN AI Commentary: Jefferies' dramatic downgrade from Buy to Hold with a $27 cut reflects skepticism that Clorox can navigate flat FY27 organic sales growth while offsetting persistent cost inflation through pricing and productivity alone, a bet increasingly questioned by bearish analysts trimming targets post-earnings, while bullish outliers maintain $150+ targets betting the GOJO integration and market-share recovery will drive earnings expansion.
Analysis by ESEN Analytics Systems (esenglobalinvest.com), an AI-driven US equity research platform covering 5,000+ US stocks.
CLX Systematic Research
Systematic screening of The Clorox Company reveals a defensive consumer staples profile marked by exceptional capital structure efficiency alongside pronounced leverage concerns. The company's ROE of 453.68% stands as the most distinctive metric, driven by negative tangible equity resulting from acquisitions and shareholder distributions—a capital structure amplified by the debt-to-equity ratio of 7.86, which substantially exceeds typical consumer products benchmarks and flags elevated financial risk.
Profitability metrics demonstrate operational resilience despite recent headwinds. The gross margin of 43.85% and net margin of 11.18% reflect pricing power in household essentials, while ROA of 13.07% indicates effective asset deployment. However, the model flags revenue contraction of -3.69% year-over-year, suggesting market share pressures or category softness in core cleaning and disinfection segments. Positive EPS growth of 10.56% indicates margin expansion offsetting top-line weakness, though sustainability depends on volume stabilization.
The current ratio of 0.84 presents liquidity concerns, falling below the 1.0 threshold and constraining financial flexibility. Combined with elevated leverage, this metric warrants monitoring during refinancing cycles or demand volatility. The beta of 0.55 confirms low correlation with broader equity markets, aligning with defensive characteristics sought during uncertainty.
Relative to peers PG, CL, and KMB, Clorox trades at a P/E of 15.36—potentially reflecting discounted valuation versus larger diversified competitors. The price-to-sales ratio of 1.72 and current price of $95.53 (down 25% from 52-week highs) position the stock in value territory, though fundamental improvement in revenue trajectory remains critical for multiple expansion.
Analysis updated monthly based on systematic screening of fundamentals, profitability, growth, and peer positioning.